Tempus AI, Inc., a technology company leading the adoption of AI to advance precision medicine and patient care, announced a new collaboration with the Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL). The collaboration aims to develop and make available a real-world multimodal, deidentified FL data library in Lens – Tempus’ data analytics platform – through which researchers may derive AI-driven insights to accelerate the development of FL treatments in an effort to improve patient outcomes.
IFLI is committed to supporting advances in understanding the biology of FL patients who are at high risk of cancer progression and enhancing therapeutic development to address critical unmet needs in the management of this disease. The collaboration will initially focus on prospectively generating multimodal FL data, particularly for POD24 patients who experience disease progression within 24 months of treatment, through a Tempus-sponsored study.
The availability of a follicular lymphoma data library has the potential to improve researchers’ understanding of the disease’s biology. Providing researchers with access to robust multimodal data supports their work in uncovering critical insights into the heterogeneity of FL, which may lead to the development of more targeted precision medicines. A comprehensive understanding of the disease is crucial for tailoring treatments to individual patient profiles, enhancing outcomes, and advancing the fight against this complex disease.
Also Read: Capgemini Unveils Gen AI to Boost the Bioeconomy
“This collaboration exemplifies the power of combining IFLI’s specialized focus on FL with Tempus’ cutting-edge AI-enabled solutions,” said Kate Sasser, PhD, Chief Scientific Officer at Tempus. “We are excited to work with IFLI and explore a new way of working with foundations to advance research. By leveraging our combined expertise and reach, we aim to create a centralized and dynamic data library that enables researchers to better understand FL.”
“IFLI is thrilled to announce our collaboration with Tempus, chosen for their exceptional leadership in the field. Together, we aim to create a robust, de-identified FL database, accelerating research and drug development to ultimately find a cure for the FL patient community,” said David McCullagh, Managing Director at IFLI. “ We believe Tempus is uniquely positioned to develop this comprehensive FL database, making it accessible to professionals in the field to combat this disease effectively.”
Source: Businesswire
